QBX258

Phase 2Small molecule

Novartis

QBX258 is one of 35 small molecule programs targeting Breast Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

AsthmaActive, not recruiting

Breast CancerPreclinical

Active, not recruiting

AsthmaPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Lexiscan

Astellas

Preclinical

1 2

Spravato

WWim Janssens

Preclinical

2 3

QBX258

Novartis

Phase 2

1 4

Tricor

JJagotec

Preclinical

1 5

Nubain

AAultman Health Foundation

Preclinical

1 6

Vfend

PPrism Pharmaceuticals

Paracetamol

1 8

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 9

Perflutren Lipid Microcpheres

TThomas Jefferson University

Preclinical

2 10

Tianeptine

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Breast Cancer1 trial

Immunotherapy for the Treatment of Breast Cancer Related Upper Extremity Lymphedema (BCRL)

Completed·MMemorial Sloan Kettering Cancer Center·N/A·NCT02494206·9 enrolled

Asthma1 trial

A Study to Establish the Efficacy of QBX258 in Patients With Moderate to Severe Asthma

Completed· Novartis logo

Novartis·Phase 2·NCT01479595·65 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for QBX258. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — QBX258 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for QBX258. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Novartis

QBX258

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Breast Cancer1 trial

Asthma1 trial

References

Drug Info

Quick Facts

Related News